MedTrace Logo

An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

NCT01782690 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 338

Last updated 2018-07-23

Study results available
· View outcomes & findings →

Summary

This observational study will evaluate the impact of rash on survival of patients with metastatic pancreatic cancer treated with erlotinib plus gemcitabine. Further, clinical effectiveness, efficacy and safety will be assessed. Data will be collected for 12 months.

Conditions

Interventions

DRUG

erlotinib

Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)

DRUG

gemcitabine

Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01782690 on ClinicalTrials.gov